CagriSema’s 25% Weight Loss in Women Is Only Half the Story
Novo Nordisk’s latest CagriSema data put a big number on the board, but the more interesting signal may be what happened when researchers looked at women across menopause.
On The Pen | GLP-1 & Obesity Medicine News
On The Pen Patient Tool
Find My Trial
Find obesity and metabolic clinical trials that may be relevant to you, then connect directly with the study team when contact information is available.
Find My Trial15,328 recruiting studies tracked across 923 treatments — sourced from ClinicalTrials.gov.
Top Stories
The most-read On The Pen stories, ranked by reader engagement.
REBRAND: Novo Drops the Nordisk, Flip Its Logo, but Can It Flip the GLP-1 Race?
Novo will aslo add the tagline “Lasting health starts now”… Here’s how they could actually make that a reality.
Latest News
What Happens to GLP-1 Heart Protection When Treatment Stops
If you have followed On The Pen for any length of time, you have heard us talk about the cardiovascular benefits of GLP-1 drugs again and again.
The Weekly Dose
On The Pen's flagship podcast — obesity medicine, unfiltered.
Recent Livestreams
Obesity.News
Stay ahead of obesity medicine.
Breaking GLP-1 news, drug development, access updates, and patient-centered analysis, all in one place.
- Breaking obesity medicine and GLP-1 news
- The latest from The Weekly Dose podcast
- Live talk show every Monday, Wednesday, and Friday at 11 AM CT
- Deeper reporting and analysis for paid subscribers
Empowering you to have better conversations with your doctor.
On The Pen covers obesity medicine from the patient's side of the exam table — GLP-1s, access, and the science, reported plainly.
Sponsors & Partners